

# Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients

NCT06833463

---

**Status** RECRUITING  
**Sponsor** Chiesi Poland Sp. z o.o.  
**Enrollment** 120 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Age e 18 years
- Recipients of a kidney transplant from a living or deceased donor
- Standard immunosuppressive regimen post-kidney transplantation (KTx) including Envarsus®
- LCP Tacrolimus therapy initiated from the day of KTx or conversion from another tacrolimus formulation to LCP Tacrolimus by day 8 at the latest, according to the institution's routine practice
- Informed patient consent to participate in the study

### Exclusion (7)

- Diagnosis of diabetes (type 1 or type 2) treated with diet or glucose-lowering drugs
- Random glycemia/HbA1c levels justifying a diagnosis of diabetes at the time of study enrollment
- Kidney retransplantation
- Recipients of a multi-organ transplant
- Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss
- ... and 2 more (see full listing online)

## Locations (6 total)

---

Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk, Gdansk, Poland  
Clinical Department of Nephrology, Dialysis, Transplantology and Internal Medicine, Krakow, Poland  
Department of Internal Diseases and Transplant Nephrology, Medical University of Lodz, Lodz, Poland  
... and 3 more locations

---

<https://clinicaltrials.gov/study/NCT06833463>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).